Jazz Pharmaceuticals: Is its Strong 47% One-Year Share Price Return Reflected in its Pricing?

Jazz Pharmaceuticals has seen a 47.2% return over the past year. The stock's current price of $182.69 is 76.5% undervalued according to a discounted cash flow (DCF) analysis. The DCF model estimates an intrinsic value of $776.61 per share. The company's position in the pharmaceuticals and biotech space and its pipeline and product portfolio support the current share price.